Lung cancer vaccine could be coming soon, UK human trial begins

Lung Cancer Vaccine: The world’s first vaccine to eliminate lung cancer could be here very soon. Human trials of this lung cancer vaccine have begun. The name of this vaccine is BNT116, manufactured by BioNTech. This vaccine is intended for the treatment of non-small cell lung cancer (NSCLC). The first phase of BNT116 trial is underway at 34 sites in the UK, US, Germany, Hungary, Poland, Spain and Turkey.

Let us tell you that the leading cause of cancer deaths worldwide is lung cancer. Due to this, approximately 1.8 million deaths occur every year. Let us know everything about this vaccine…

Human trial of lung cancer vaccine

The first UK patient was vaccinated on Tuesday. Around 130 patients in Britain will receive BNT116 alongside immunotherapy at various stages of lung cancer. Using the same mRNA technology as the COVID-19 vaccine, BNT116 aims to enable the immune system to target NSCLC tumour markers, attacking cancer cells while sparing healthy cells.

How did the lung cancer vaccine trial go?

Janus Raz, a 67-year-old AI scientist from London, was the first UK patient to receive the vaccine. He decided to take part in the trial after being diagnosed with lung cancer in May and starting chemotherapy and radiotherapy. Rax received six injections over 30 minutes at the National Institute for Health Research (UCLH) Clinical Research Centre. Each of them had different strands of RNA. They will receive the vaccine every week for 6 weeks. After that, the treatment will be given every 3 weeks for more than a year.

what do doctors say

Professor Seo Ming, from University College London Hospitals NHS Foundation Trust (UCLH), told the Guardian: “We are entering a new era with mRNA-based immunotherapy for lung cancer.” Professor Seo Ming Lee, a consultant medical oncologist at University College London Hospitals NHS Foundation Trust, who is leading the UK trial, said the aim was to prevent lung cancer from coming back, which often happens after surgery and radiotherapy. He said: “I have been studying lung cancer for 40 years.

In the 1990s, chemotherapy was questionable. We now know that 20-30% of stage 4 patients survive immunotherapy. This mRNA vaccine is expected to increase survival rates further. This trial is part of the UK’s efforts to rapidly advance innovative cancer vaccine trials in patients through the new NHS Matching Scheme, which is vital for patients’ lives.

Disclaimer: Some information given in the news is based on media reports. Before implementing any suggestion, you must consult the concerned expert.

Also read: Monkeypox: What would be the impact if Monkeypox came to India, know how its entry can be banned